Dupilumab in Elderly Patients With Severe Atopic Dermatitis

杜皮鲁玛 湿疹面积及严重程度指数 医学 特应性皮炎 耐受性 皮肤科生活质量指数 瘙痒的 皮肤病科 生活质量(医疗保健) 入射(几何) 人口 内科学 不利影响 银屑病 物理 护理部 环境卫生 光学
作者
Filomena Russo,Nicola Milanesi,Alessandra Cartocci,Francesco Bruzziches,Greta Tronconi,Laura Lazzeri,Angelo Massimiliano D’Erme,Giovanni Bagnoni,Massimo Gola,Élisa Cinotti,Pietro Rubegni,Maria Laura Flori
出处
期刊:Dermatitis [Lippincott Williams & Wilkins]
卷期号:32 (1S): S24-S27 被引量:20
标识
DOI:10.1097/der.0000000000000686
摘要

BACKGROUND: Atopic dermatitis (AD) in the elderly has been poorly investigated, although its incidence is gradually increasing mainly in industrialized countries. Age-specific factors in older patients must be considered when selecting treatment options. OBJECTIVES: To evaluate the efficacy and tolerability of dupilumab in treating elderly patients with severe AD. METHODS: This was a retrospective, multicenter study involving 26 elderly patients (age, ≥65 years) with severe AD who were treated with dupilumab for at least 16 weeks. Absolute and percentage frequencies were used to evaluate qualitative variables and mean and SD for quantitative ones. For Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale (NRS), and Dermatology Life Quality Index (DLQI), the median was also calculated. Wilcoxon test was used to evaluate the variations in EASI, Pruritus NRS, and DLQI observed between the 2 examinations. RESULTS: After 4 months of therapy, the majority of patients showed a significant improvement in EASI (64.4%), Pruritus NRS (58.2%), and DLQI (44.9%). Only 11% of patients reported mild or moderate conjunctivitis. CONCLUSIONS: To the best of our knowledge, this is the first study concerning the use of dupilumab in the elderly with severe AD. Our data show the effectiveness of dupilumab in this particular population with a lower percentage of conjunctivitis than observed in studies on adults and also excellent control of itching. Only larger, controlled case studies will be able to clarify whether the dosage or frequency of administration of dupilumab in these patients should be different from the protocol used for adults.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
斯文败类的应助被科研通管家采纳,获得10
刚刚
邦尼老师完成签到,获得积分10
刚刚
炒米粉完成签到,获得积分0
刚刚
刚刚
李爱国的应助被科研通管家采纳,获得10
刚刚
聂的苏发布了新的文献求助50
刚刚
慕青的应助被二马三乡采纳,获得10
1秒前
1秒前
liubole完成签到,获得积分10
1秒前
1秒前
2秒前
wanci的应助被呼呼呼呼采纳,获得10
2秒前
2秒前
cc完成签到,获得积分20
3秒前
3秒前
小蘑菇的应助被能干的故事采纳,获得10
3秒前
3秒前
4秒前
4秒前
4秒前
兰瓜瓜完成签到,获得积分10
5秒前
5秒前
molihuakai的应助被Kraghc采纳,获得10
5秒前
6秒前
氨气发布了新的文献求助10
6秒前
小晶完成签到,获得积分10
6秒前
sy发布了新的文献求助10
6秒前
6秒前
Ava的应助被yanzi采纳,获得10
6秒前
7秒前
蔡慧学发布了新的文献求助10
7秒前
嘻嘻嘻发布了新的文献求助50
7秒前
RGG完成签到,获得积分10
8秒前
8秒前
Leo89完成签到,获得积分10
8秒前
慕青的应助被Jennie采纳,获得10
8秒前
huanhuan发布了新的文献求助10
9秒前
caoxiongfeng_512完成签到,获得积分10
9秒前
张亚慧发布了新的文献求助10
9秒前
靓丽芙蓉发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417